- Previous Close
1.4300 - Open
1.4300 - Bid --
- Ask --
- Day's Range
1.4100 - 1.4300 - 52 Week Range
0.8080 - 1.9000 - Volume
7,615 - Avg. Volume
165,156 - Market Cap (intraday)
48.156M - Beta (5Y Monthly) -3.68
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.00
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
okyopharma.comRecent News: OKYO
View More
Performance Overview: OKYO
Trailing total returns as of 3/10/2025, which may include dividends or other distributions. Benchmark is S&P 500 .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OKYO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OKYO
View MoreValuation Measures
Market Cap
48.36M
Enterprise Value
47.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.69M
Diluted EPS (ttm)
-0.3800
Balance Sheet and Cash Flow
Total Cash (mrq)
987.2k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Research Analysis: OKYO
View MoreCompany Insights: OKYO
OKYO does not have Company Insights